Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

Next Previous
Trial Profile

A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs DNL-201 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Denali Therapeutics Inc

    • Most Recent Events

    • 10 Dec 2018 According to a Denali Therapeutics Inc media release, dosing has been initiated in this trial. Data readout from this study is expected during Q4 2019.
    • 08 Nov 2018 According to a Denali Therapeutics Inc media release, first patient expected to be dosed in late 2018.
    • 08 Nov 2018 Status changed from not yet recruiting to recruiting, according to a Denali Therapeutics Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top